Pereira, Joana B. http://orcid.org/0000-0002-4604-2711
Janelidze, Shorena
Strandberg, Olof
Whelan, Christopher D. http://orcid.org/0000-0003-0308-5583
Zetterberg, Henrik http://orcid.org/0000-0003-3930-4354
Blennow, Kaj http://orcid.org/0000-0002-1890-4193
Palmqvist, Sebastian http://orcid.org/0000-0002-9267-1930
Stomrud, Erik
Mattsson-Carlgren, Niklas http://orcid.org/0000-0002-8885-7724
Hansson, Oskar http://orcid.org/0000-0001-8467-7286
Funding for this research was provided by:
Knut och Alice Wallenbergs Stiftelse (2017-0383, 2015.0125)
Hjärnfonden (FO2021-0293)
Alzheimerfonden (AF-939932)
Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse (2020-0314)
Article History
Received: 24 May 2022
Accepted: 7 October 2022
First Online: 28 November 2022
Competing interests
: Siemens Healthineers, Roche, Abbvie, Novo Nordisk, Apellis, CogRx, Denali, Red Abbey Labs, Samumed, Annexon, Eisai, Passage Bio, Nervgen, Alector, Pinteon Therapeutics, Artery Therapeutics, AZTherapies, Triplet Therapeutics and Wave included H.Z. as a member of their scientific advisory boards and/or as a consultant. Moreover, lectures in symposia sponsored by Fujirebio, Cellectricon, Biogen, Alzecure and Roche were given by H.Z., who is a cofounder of Brain Biomarker Solutions in Gothenburg AB (BBS) (part of the GU Ventures Incubator Program). Roche Diagnostics, Abcam, BioArctic, Lilly, Biogen, Axon, MagQu, Julius Clinical, Novartis and Siemens Healthineers, and as a cofounder of Brain Biomarker Solutions in Gothenburg AB (BBS) (part of the GU Ventures Incubator Program), included K.B. as a consultant, at advisory boards or at data monitoring committees. ADx, AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, Fujirebio, GE Healthcare, Pfizer and Roche provided research support to O.H. Amylyx, Alzpath, Biogen, Cerveau, Fujirebio, Genentech, Roche and Siemens provided consultancy/speaker fees to O.H. The remaining authors declare no competing interests.